Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial
Bristol-Myers Squibb
Meletios A Dimopoulos; Dominik Dytfeld; Sebastian Grosicki; Philippe Moreau; Naoki Takezako; Mitsuo Hori; Xavier Leleu; Richard LeBlanc; Kenshi Suzuki; Marc S Raab; Paul G Richardson; Mihaela Popa McKiver; Ying-Ming Jou; David Yao; Prianka Das; Jesús San-Miguel